fluorecare Combo Cardiac Diagnostic Kit
fluorecare® cTnI/CK-MB/MyO Diagnostic Kit
To address the global demand for rapid cardiovascular diagnostics, Microprofit Biotech proudly introduces the cTnI/CK-MB/MyO Combo Immunofluorescence Quantitative Assay Kit. Leveraging Fluorescence Immunoassay (FIA) POCT technology, this innovative kit delivers accurate AMI diagnosis in just 15 minutes, surpassing the >60-minute turnaround time of traditional lab tests (CLIA/ECLIA). Designed for emergency rooms, ICUs, and primary care settings, it sets a new standard for efficiency in cardiac care.
Why Test cTnI, MyO, and CK-MB?
cTnI (Cardiac Troponin I)
Gold Standard for AMI Diagnosis: >95% specificity, endorsed by ESC/ACC guidelines.
MyO (Myoglobin)
Earliest Biomarker: Detectable within 1–2 hours post-symptom onset, enabling early rule-out.
CK-MB (Creatine Kinase-MB)
Reinfarction Monitoring: Short half-life (12–24 hours) ideal for detecting reocclusion.
Infarct Size Estimation: Peak levels correlate with myocardial damage extent.
Key Advantages
- Ultra-Fast Diagnosis, Saving Critical Time
- Results in 15 minutes vs. >60 minutes for central lab tests, drastically reducing door-to-balloon (D2B) time.
- Cost-Effective & Streamlined Workflow
- Single-test triplex detection replaces sequential single-marker assays, cutting costs and complexity.
- Comprehensive AMI Coverage
- MyO (early screening) ? cTnI (confirmation) ? CK-MB (reinfarction monitoring) – seamless tracking of AMI progression.
- Flexible Sample Types, No Centrifugation
- Compatible with whole blood/serum/plasma, ideal for resource-limited settings.
- CE Certified, compliant with ISO 13485.
Reliable & Accurate
Clinical validation shows >95% concordance with CLIA .
Applications
- ERs & Chest Pain Centers: Rapid triage for ACS protocols.
- ICUs/CCUs: Post-operative myocardial injury monitoring.
- Primary Hospitals & Ambulances: Lab-independent AMI screening.
- Disaster & Battlefield Medicine: Portable for field emergencies.